Research progress of seven tumor-associated autoantibodies in lung cancer diagnosis
10.13431/j.cnki.immunol.j.20250028
- VernacularTitle:7种肿瘤相关自身抗体在肺癌诊断中应用的研究进展
- Author:
Lirong CUI
1
;
Weiping MA
1
;
Xiang ZHANG
1
Author Information
1. 810001 西宁,青海大学附属医院检验科
- Publication Type:Journal Article
- Keywords:
Lung cancer;
Tumor-associated autoantibodies;
Diagnosis;
Combined detection
- From:
Immunological Journal
2025;41(3):193-198
- CountryChina
- Language:Chinese
-
Abstract:
Lung cancer is one of the leading causes of cancer-related death worldwide.In China,the incidence and mortality rates of lung cancer are constantly rising.Effective screening and diagnostic methods are crucial for improving patient survival rates.Currently,the early screening methods for lung cancer are insufficient.Serum tumor markers as conventional screening indicators,have relatively low sensitivity and are mainly used for monitoring treatment efficacy and prognosis.Tumor-associated autoantibodies(TAAbs)as emerging biomarkers,include seven types:p53,PGP9.5,SOX2,GAGE7,GBU4-5,MAGE A1 and CAGE.Due to their detectability in the early stage of lung cancer,long half-life,high sensitivity and specificity,they have attracted extensive attention from researchers.This article reviews the generation mechanisms,characteristics and the applications of these seven TAAbs in the diagnosis of lung cancer.Based on domestic and international research,this paper reviews the sensitivity and specificity of these autoantibodies in the diagnosis of lung cancer,and focuses the development of multi-factor combined detection strategies,the combination of traditional tumor markers and imaging techniques(such as low-dose CT)to further enhance the diagnostic efficiency of lung cancer,aiming to achieve early and accurate diagnosis.
